CancerNetwork®’s Week in Review: May 3, 2021

Look back at some of the important news and notes from last week in the world of oncology, featuring articles from live events, the latest issue of the Journal ONCOLOGY®, and an episode of “Oncology Peer Review On-The-Go.”

Each Monday, CancerNetwork® highlights the most important content from the previous week in oncology news.

The top articles from last week include features from the Journal ONCOLOGY®’s latest issue. An article on optimizing molecular testing for non–small cell lung cancer headlines a list of compelling features, with the top 5 rounded out with the latest episode of CancerNetwork®’s podcast.

Strategies for Optimizing Molecular Testing in Non-Small Cell Lung Cancer

As genomic profiling becomes more and more essential as part of clinical decision making, clinicians are challenged to stay abreast of advancements in this space to improve patient outcomes and advance the field of precision oncology.

The advent of next-generation sequencing has been a key driver in treatment advances and improved outcomes for patients with non–small cell lung cancer. However, implementation of universal molecular testing for patient populations who may benefit the most has been somewhat limited, with long turnaround times and lack of adequate tissue noted as 2 of the main causes.

New Potential Frontline Standards for RCC Are Spotlighted at Genitourinary Cancers Symposium

ONCOLOGY® reviews key updates in the treatment of renal cell carcinoma to come out of the Genitourinary Cancers Symposium.

Namely, the readout of the phase 3 CLEAR trial demonstrated that combining lenvatinib (Lenvima) with either pembrolizumab (Keytruda) or everolimus (Afinitor) improved progression-free survival and objective response rate over sunitinib (Sutent) for the treatment of patients with advanced renal cell carcinoma receiving therapy in the frontline setting.

Around the Practice: Relapsed/Refractory HER2+ Metastatic Breast Cancer

Experts discusses the treatment of patients with HER2-positive breast cancer in a virtual CancerNetwork® Around the Practice presentation, “Relapsed/Refractory HER2+ Metastatic Breast Cancer,” held January 21, 2021, and moderated by Adam M. Brufsky, MD, PhD.

The presentation also included an interactive online platform for members of the audience to submit responses to polling questions that were subsequently discussed by the panelists.

Francesco Ravera, MD, PhD, on the Rationale for Comparing cfDNA to MRI for Predicting pCR After Neoadjuvant Therapy in Breast Cancer

CancerNetwork® spoke with Francesco Ravera, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 to discuss a study that looked at cell-free DNA assessment compared with traditional MRI for determining pathological complete response in patients with locally advanced breast cancer.

Oncology Peer Review On-The-Go: Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics

CancerNetwork®’s latest podcast episode dissects and article from the journal ONCOLOGY® focusing on 4 PARP inhibitors investigated for the treatment of advanced prostate cancer.

Corresponding author, Jun Gong, MD, a medical oncologist at Cedars-Sinai Medical Center, discussed the 4 PARP inhibitors that have undergone significant investigation for the treatment of patients with metastatic castrate-resistant prostate cancer. While elaborating on the use of PARP inhibitors, Gong also discussed the importance and potential value of successfully integrating these agents into prostate cancer practice.

For more updates from CancerNetwork®, make sure to follow us on Facebook, Twitter, and LinkedIn to stay up to date on the latest in oncology.

Related Videos
Although opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.
An expert from Dana-Farber Cancer Institute says that policymakers and insurers should take a hard look at policies that restrict opioid use in patients with cancer who are at end of life, especially for underserved communities.
After assessing racial disparities in opioid access in older patients with cancer, an expert from Dana-Farber Cancer Institute speaks to the need for examining younger populations and those with different insurance types.
An expert from Dana-Farber Cancer Institute states that although giving opioids for minor procedures could lead to substance abuse issues, use of the drugs to manage end of life cancer pain should not be up for debate.
An expert from Dana-Farber Cancer Institute discusses data from a study investigating racial inequities in opioid access among patients of cancer near the end of life.
An expert from Dana-Farber Cancer Institute describes several key strategies for mitigating racial disparities in opioid access among patients with cancer near end of life.
Expert in oncology
Expert in oncology
Related Content